DK2364734T3
(en)
*
|
2000-07-21 |
2017-10-30 |
Revance Therapeutics Inc |
Biological multicomponent transport systems
|
US20040220100A1
(en)
*
|
2000-07-21 |
2004-11-04 |
Essentia Biosystems, Inc. |
Multi-component biological transport systems
|
GB0103110D0
(en)
*
|
2000-08-25 |
2001-03-28 |
Aventis Pharma Inc |
A membrane penetrating peptide encoded by a nuclear localization sequence from human period 1
|
US20040126900A1
(en)
*
|
2001-04-13 |
2004-07-01 |
Barry Stephen E |
High affinity peptide- containing nanoparticles
|
US6939564B2
(en)
*
|
2001-06-08 |
2005-09-06 |
Labopharm, Inc. |
Water-soluble stabilized self-assembled polyelectrolytes
|
US7094810B2
(en)
*
|
2001-06-08 |
2006-08-22 |
Labopharm, Inc. |
pH-sensitive block copolymers for pharmaceutical compositions
|
US7030127B2
(en)
|
2001-06-29 |
2006-04-18 |
Ethicon, Inc. |
Composition and medical devices utilizing bioabsorbable polymeric waxes
|
US7034037B2
(en)
|
2001-06-29 |
2006-04-25 |
Ethicon, Inc. |
Compositions and medical devices utilizing bioabsorbable polymeric waxes and rapamycin
|
US6967234B2
(en)
|
2002-12-18 |
2005-11-22 |
Ethicon, Inc. |
Alkyd-lactone copolymers for medical applications
|
CN1194704C
(zh)
*
|
2001-11-12 |
2005-03-30 |
华东理工大学 |
含有活性药物、主链中具有氨基酸的聚酯及其制备方法
|
WO2003078576A2
(en)
*
|
2002-03-12 |
2003-09-25 |
Nitto Denko Corporation |
Vector for transfection of eukaryotic cells
|
US7326426B2
(en)
|
2002-03-29 |
2008-02-05 |
Ethicon, Inc. |
Compositions and medical devices utilizing bioabsorbable liquid polymers
|
US7005136B2
(en)
|
2002-03-29 |
2006-02-28 |
Ethicon, Inc. |
Bone replacement materials utilizing bioabsorbable liquid polymers
|
US7374930B2
(en)
*
|
2002-05-21 |
2008-05-20 |
Expression Genetics, Inc. |
GLP-1 gene delivery for the treatment of type 2 diabetes
|
US7368125B2
(en)
|
2002-06-05 |
2008-05-06 |
Ethicon, Inc. |
Amphiphilic polymers for medical applications
|
US7026374B2
(en)
|
2002-06-25 |
2006-04-11 |
Aruna Nathan |
Injectable microdispersions for medical applications
|
US7101566B2
(en)
|
2002-06-28 |
2006-09-05 |
Ethicon, Inc. |
Polymer coated microparticles for sustained release
|
DE60333228D1
(de)
*
|
2002-12-02 |
2010-08-12 |
Amgen Fremont Inc |
Gegen den tumor nekrose faktor gerichtete antikörper und deren verwendungen
|
US6872799B2
(en)
|
2002-12-18 |
2005-03-29 |
Ethicon, Inc. |
Functionalized polymers for medical applications
|
US6866860B2
(en)
|
2002-12-19 |
2005-03-15 |
Ethicon, Inc. |
Cationic alkyd polyesters for medical applications
|
CA2517576A1
(en)
*
|
2003-03-06 |
2004-09-23 |
John H. Shadduck |
Adaptive optic lens and method of making
|
US7309757B2
(en)
*
|
2003-06-20 |
2007-12-18 |
Agency For Science, Technology And Research |
Polymers for the delivery of bioactive agents and methods of their preparation
|
WO2005007819A2
(en)
*
|
2003-07-09 |
2005-01-27 |
Wisconsin Alumni Research Foundation |
Charge-dynamic polymers and delivery of anionic compounds
|
US9211248B2
(en)
|
2004-03-03 |
2015-12-15 |
Revance Therapeutics, Inc. |
Compositions and methods for topical application and transdermal delivery of botulinum toxins
|
US8974774B2
(en)
*
|
2004-03-03 |
2015-03-10 |
Revance Therapeutics, Inc. |
Compositions and methods for topical diagnostic and therapeutic transport
|
HUE025656T2
(en)
|
2004-03-03 |
2016-04-28 |
Revance Therapeutics Inc |
Topical application of botulotoxins and transdermal delivery
|
EP4005601A1
(en)
|
2004-12-22 |
2022-06-01 |
Nitto Denko Corporation |
Drug carrier and drug carrier kit for inhibiting fibrosis
|
US20120269886A1
(en)
|
2004-12-22 |
2012-10-25 |
Nitto Denko Corporation |
Therapeutic agent for pulmonary fibrosis
|
ZA200707352B
(en)
|
2005-03-03 |
2009-04-29 |
Revance Therapeutics Inc |
Compositions and methods for topical application and transdermal delivery of botulinum toxins
|
US8349991B2
(en)
*
|
2005-04-19 |
2013-01-08 |
Massachusetts Institute Of Technology |
Amphiphilic polymers and methods of use thereof
|
US20080184618A1
(en)
*
|
2005-08-03 |
2008-08-07 |
Amcol International |
Virus-Interacting Layered Phyllosilicates and Methods of Use
|
US20100272769A1
(en)
*
|
2005-08-03 |
2010-10-28 |
Amcol International |
Virus-, Bacteria-, and Fungi-Interacting Layered Phyllosilicates and Methods of Use
|
US20070031512A1
(en)
*
|
2005-08-03 |
2007-02-08 |
Amcol International Corporation |
Virus-interacting layered phyllosilicates and methods of inactivating viruses
|
US8518414B2
(en)
*
|
2005-11-17 |
2013-08-27 |
Revance Therapeutics, Inc. |
Compositions and methods of topical application and transdermal delivery of botulinum toxins with reduced non-toxin proteins
|
US9572886B2
(en)
|
2005-12-22 |
2017-02-21 |
Nitto Denko Corporation |
Agent for treating myelofibrosis
|
FR2899231B1
(fr)
*
|
2006-04-03 |
2008-09-05 |
Isochem Sa |
NOUVEAUX O-CARBOXY ANHYDRIDES (OCAs) A FONCTION SALIFIABLE ET POLYMERES OBTENUS A PARTIR DE CES OCAs
|
US8124598B2
(en)
*
|
2006-09-14 |
2012-02-28 |
Sharon Sageman |
7-keto DHEA for psychiatric use
|
MX2009003092A
(es)
*
|
2006-09-22 |
2009-05-08 |
Labopharm Inc |
Composiciones y metodos para suministro de farmaco dirigido a ph.
|
AU2007340162B2
(en)
*
|
2006-12-29 |
2013-08-01 |
Revance Therapeutics, Inc. |
Compositions and methods of topical application and transdermal delivery of botulinum toxins stabilized with polypeptide fragments derived from HIV-TAT
|
BRPI0720729A2
(pt)
*
|
2006-12-29 |
2014-04-08 |
Revance Therapeutics Inc |
Moléculas de transporte que utilizam polipeptídeos hiv-tat de sequência inversa.
|
US8834918B2
(en)
*
|
2007-01-22 |
2014-09-16 |
Wisconsin Alumni Research Foundation |
Modified multilayered film
|
TWI407971B
(zh)
|
2007-03-30 |
2013-09-11 |
Nitto Denko Corp |
Cancer cells and tumor-related fibroblasts
|
EP2431043A1
(en)
*
|
2007-05-23 |
2012-03-21 |
Amcol International Corporation |
Cholesterol-interacting layered phyllosilicates for suppressing gastrointestinal cholesterol absorption
|
US20100160274A1
(en)
*
|
2007-09-07 |
2010-06-24 |
Sharon Sageman |
7-KETO DHEA for Psychiatric Use
|
CA2698812A1
(en)
|
2007-09-14 |
2009-03-19 |
Nitto Denko Corporation |
Drug carriers
|
US20090105375A1
(en)
|
2007-10-09 |
2009-04-23 |
Lynn David M |
Ultrathin Multilayered Films for Controlled Release of Anionic Reagents
|
US8324333B2
(en)
|
2008-06-05 |
2012-12-04 |
Wisconsin Alumni Research Foundation |
Anionic charge-dynamic polymers for release of cationic agents
|
EP2396365A4
(en)
*
|
2009-02-11 |
2013-10-30 |
Univ Houston |
REDUCABLE POLYMERS FOR THE ADMINISTRATION OF NON-VIRAL GENES
|
US8470891B2
(en)
*
|
2009-12-23 |
2013-06-25 |
International Business Machines Corporation |
Biodegradable block polymers for drug delivery, and methods related thereto
|
EP3578205A1
(en)
|
2010-08-06 |
2019-12-11 |
ModernaTX, Inc. |
A pharmaceutical formulation comprising engineered nucleic acids and medical use thereof
|
WO2012045082A2
(en)
|
2010-10-01 |
2012-04-05 |
Jason Schrum |
Engineered nucleic acids and methods of use thereof
|
AU2012236099A1
(en)
|
2011-03-31 |
2013-10-03 |
Moderna Therapeutics, Inc. |
Delivery and formulation of engineered nucleic acids
|
US9464124B2
(en)
|
2011-09-12 |
2016-10-11 |
Moderna Therapeutics, Inc. |
Engineered nucleic acids and methods of use thereof
|
EP3682905B1
(en)
|
2011-10-03 |
2021-12-01 |
ModernaTX, Inc. |
Modified nucleosides, nucleotides, and nucleic acids, and uses thereof
|
DK2791160T3
(da)
|
2011-12-16 |
2022-05-30 |
Modernatx Inc |
Modificerede mrna-sammensætninger
|
US9572897B2
(en)
|
2012-04-02 |
2017-02-21 |
Modernatx, Inc. |
Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
|
US9283287B2
(en)
|
2012-04-02 |
2016-03-15 |
Moderna Therapeutics, Inc. |
Modified polynucleotides for the production of nuclear proteins
|
DE18200782T1
(de)
|
2012-04-02 |
2021-10-21 |
Modernatx, Inc. |
Modifizierte polynukleotide zur herstellung von proteinen im zusammenhang mit erkrankungen beim menschen
|
CA2868391A1
(en)
|
2012-04-02 |
2013-10-10 |
Stephane Bancel |
Polynucleotides comprising n1-methyl-pseudouridine and methods for preparing the same
|
US9878056B2
(en)
|
2012-04-02 |
2018-01-30 |
Modernatx, Inc. |
Modified polynucleotides for the production of cosmetic proteins and peptides
|
HRP20220607T1
(hr)
|
2012-11-26 |
2022-06-24 |
Modernatx, Inc. |
Terminalno modificirana rna
|
WO2014113089A2
(en)
|
2013-01-17 |
2014-07-24 |
Moderna Therapeutics, Inc. |
Signal-sensor polynucleotides for the alteration of cellular phenotypes
|
GB201304245D0
(en)
*
|
2013-03-08 |
2013-04-24 |
Inst Quimic De Sarria |
Chemical compounds
|
US20160024181A1
(en)
|
2013-03-13 |
2016-01-28 |
Moderna Therapeutics, Inc. |
Long-lived polynucleotide molecules
|
US10258698B2
(en)
|
2013-03-14 |
2019-04-16 |
Modernatx, Inc. |
Formulation and delivery of modified nucleoside, nucleotide, and nucleic acid compositions
|
US8980864B2
(en)
|
2013-03-15 |
2015-03-17 |
Moderna Therapeutics, Inc. |
Compositions and methods of altering cholesterol levels
|
PL3019619T3
(pl)
|
2013-07-11 |
2022-01-10 |
Modernatx, Inc. |
Kompozycje zawierające syntetyczne polinkleotydy kodujące białka powiązane z crispr i syntetyczne sgrna oraz sposoby ich stosowania
|
JP2016530294A
(ja)
|
2013-09-03 |
2016-09-29 |
モデルナ セラピューティクス インコーポレイテッドModerna Therapeutics,Inc. |
キメラポリヌクレオチド
|
US20160194368A1
(en)
|
2013-09-03 |
2016-07-07 |
Moderna Therapeutics, Inc. |
Circular polynucleotides
|
WO2015048744A2
(en)
|
2013-09-30 |
2015-04-02 |
Moderna Therapeutics, Inc. |
Polynucleotides encoding immune modulating polypeptides
|
EP3052521A1
(en)
|
2013-10-03 |
2016-08-10 |
Moderna Therapeutics, Inc. |
Polynucleotides encoding low density lipoprotein receptor
|
US20160367638A1
(en)
|
2013-12-19 |
2016-12-22 |
Crystal BYERS |
LEPTIN mRNA COMPOSITIONS AND FORMULATIONS
|
CA2955250A1
(en)
|
2014-07-16 |
2016-01-21 |
Moderna Therapeutics, Inc. |
Chimeric polynucleotides
|
US20170210788A1
(en)
|
2014-07-23 |
2017-07-27 |
Modernatx, Inc. |
Modified polynucleotides for the production of intrabodies
|
US10494619B2
(en)
|
2014-07-31 |
2019-12-03 |
The Board Of Regents Of The University Of Oklahoma |
High isomerohydrolase activity mutants of human RPE65
|
CN105920618A
(zh)
*
|
2016-06-13 |
2016-09-07 |
上海交通大学医学院附属新华医院 |
一种生物靶向纳米基因材料及其制造方法
|
US11767520B2
(en)
|
2017-04-20 |
2023-09-26 |
Atyr Pharma, Inc. |
Compositions and methods for treating lung inflammation
|
US11485972B2
(en)
|
2017-05-18 |
2022-11-01 |
Modernatx, Inc. |
Modified messenger RNA comprising functional RNA elements
|
JP7285220B2
(ja)
|
2017-05-18 |
2023-06-01 |
モデルナティエックス インコーポレイテッド |
連結したインターロイキン-12(il12)ポリペプチドをコードするポリヌクレオチドを含む脂質ナノ粒子
|
MA49395A
(fr)
|
2017-06-14 |
2020-04-22 |
Modernatx Inc |
Polynucléotides codant pour le facteur viii de coagulation
|
EP4219715A3
(en)
|
2017-09-08 |
2023-09-06 |
MiNA Therapeutics Limited |
Stabilized cebpa sarna compositions and methods of use
|
WO2019104152A1
(en)
|
2017-11-22 |
2019-05-31 |
Modernatx, Inc. |
Polynucleotides encoding ornithine transcarbamylase for the treatment of urea cycle disorders
|
MA50802A
(fr)
|
2017-11-22 |
2020-09-30 |
Modernatx Inc |
Polynucléotides codant pour des sous-unités alpha et bêta de propionyl-coa carboxylase pour le traitement de l'acidémie propionique
|
EP3714047A2
(en)
|
2017-11-22 |
2020-09-30 |
ModernaTX, Inc. |
Polynucleotides encoding phenylalanine hydroxylase for the treatment of phenylketonuria
|
EP3735270A1
(en)
|
2018-01-05 |
2020-11-11 |
Modernatx, Inc. |
Polynucleotides encoding anti-chikungunya virus antibodies
|
WO2019197845A1
(en)
|
2018-04-12 |
2019-10-17 |
Mina Therapeutics Limited |
Sirt1-sarna compositions and methods of use
|
US20210346306A1
(en)
|
2018-05-23 |
2021-11-11 |
Modernatx, Inc. |
Delivery of dna
|
PE20210685A1
(es)
|
2018-07-03 |
2021-04-08 |
Gilead Sciences Inc |
Anticuerpos que se dirigen al gp120 de vih y metodos de uso
|
US20220184185A1
(en)
|
2018-07-25 |
2022-06-16 |
Modernatx, Inc. |
Mrna based enzyme replacement therapy combined with a pharmacological chaperone for the treatment of lysosomal storage disorders
|
US20210317461A1
(en)
|
2018-08-09 |
2021-10-14 |
Verseau Therapeutics, Inc. |
Oligonucleotide compositions for targeting ccr2 and csf1r and uses thereof
|
EP3846776A1
(en)
|
2018-09-02 |
2021-07-14 |
ModernaTX, Inc. |
Polynucleotides encoding very long-chain acyl-coa dehydrogenase for the treatment of very long-chain acyl-coa dehydrogenase deficiency
|
JP2022500436A
(ja)
|
2018-09-13 |
2022-01-04 |
モダーナティエックス・インコーポレイテッドModernaTX, Inc. |
糖原病を処置するためのグルコース−6−ホスファターゼをコードするポリヌクレオチド
|
MA53608A
(fr)
|
2018-09-13 |
2021-07-21 |
Modernatx Inc |
Polynucléotides codant pour les sous-unités e1-alpha, e1-beta et e2 du complexe alpha-cétoacide déshydrogénase à chaîne ramifiée pour le traitement de la leucinose
|
AU2019339430A1
(en)
|
2018-09-14 |
2021-04-29 |
Modernatx, Inc. |
Polynucleotides encoding uridine diphosphate glycosyltransferase 1 family, polypeptide A1 for the treatment of Crigler-Najjar Syndrome
|
US20220152225A1
(en)
|
2018-09-27 |
2022-05-19 |
Modernatx, Inc. |
Polynucleotides encoding arginase 1 for the treatment of arginase deficiency
|
US20220211740A1
(en)
|
2019-04-12 |
2022-07-07 |
Mina Therapeutics Limited |
Sirt1-sarna compositions and methods of use
|
WO2020227642A1
(en)
|
2019-05-08 |
2020-11-12 |
Modernatx, Inc. |
Compositions for skin and wounds and methods of use thereof
|
KR20220032568A
(ko)
|
2019-06-25 |
2022-03-15 |
길리애드 사이언시즈, 인코포레이티드 |
Flt3l-fc 융합 단백질 및 사용 방법
|
AU2020315598A1
(en)
|
2019-07-16 |
2022-03-03 |
Gilead Sciences, Inc. |
HIV vaccines and methods of making and using
|
BR112022005687A2
(pt)
|
2019-09-30 |
2022-06-21 |
Gilead Sciences Inc |
Vacinas contra o hbv e métodos para tratar o hbv
|
JP2023527875A
(ja)
|
2020-06-01 |
2023-06-30 |
モダーナティエックス・インコーポレイテッド |
フェニルアラニンヒドロキシラーゼバリアント及びその使用
|
EP3954393A1
(en)
|
2020-08-13 |
2022-02-16 |
Bioasis Technologies Inc. |
Combination therapies for delivery across the blood brain barrier
|
TWI815194B
(zh)
|
2020-10-22 |
2023-09-11 |
美商基利科學股份有限公司 |
介白素2-Fc融合蛋白及使用方法
|
CA3199784A1
(en)
|
2020-11-13 |
2022-05-19 |
Modernatx, Inc. |
Polynucleotides encoding cystic fibrosis transmembrane conductance regulator for the treatment of cystic fibrosis
|
WO2022204371A1
(en)
|
2021-03-24 |
2022-09-29 |
Modernatx, Inc. |
Lipid nanoparticles containing polynucleotides encoding glucose-6-phosphatase and uses thereof
|
US20240216288A1
(en)
|
2021-03-24 |
2024-07-04 |
Modernatx, Inc. |
Lipid nanoparticles containing polynucleotides encoding propionyl-coa carboxylase alpha and beta subunits and uses thereof
|
EP4314260A1
(en)
|
2021-03-24 |
2024-02-07 |
Modernatx, Inc. |
Lipid nanoparticles and polynucleotides encoding ornithine transcarbamylase for the treatment of ornithine transcarbamylase deficiency
|
WO2022204369A1
(en)
|
2021-03-24 |
2022-09-29 |
Modernatx, Inc. |
Polynucleotides encoding methylmalonyl-coa mutase for the treatment of methylmalonic acidemia
|
WO2022204390A1
(en)
|
2021-03-24 |
2022-09-29 |
Modernatx, Inc. |
Lipid nanoparticles containing polynucleotides encoding phenylalanine hydroxylase and uses thereof
|
US20240175033A1
(en)
|
2021-03-26 |
2024-05-30 |
Mina Therapeutics Limited |
TMEM173 saRNA Compositions and Methods of Use
|
EP4355882A2
(en)
|
2021-06-15 |
2024-04-24 |
Modernatx, Inc. |
Engineered polynucleotides for cell-type or microenvironment-specific expression
|
WO2022271776A1
(en)
|
2021-06-22 |
2022-12-29 |
Modernatx, Inc. |
Polynucleotides encoding uridine diphosphate glycosyltransferase 1 family, polypeptide a1 for the treatment of crigler-najjar syndrome
|
EP4408871A1
(en)
|
2021-10-01 |
2024-08-07 |
ModernaTX, Inc. |
Polynucleotides encoding relaxin for the treatment of fibrosis and/or cardiovascular disease
|
WO2023099884A1
(en)
|
2021-12-01 |
2023-06-08 |
Mina Therapeutics Limited |
Pax6 sarna compositions and methods of use
|
CN114452266B
(zh)
*
|
2022-02-09 |
2023-05-19 |
南京凯玛生物科技有限公司 |
一种基于重组核糖体蛋白的核酸药物递送系统及其制备方法和应用
|
WO2023170435A1
(en)
|
2022-03-07 |
2023-09-14 |
Mina Therapeutics Limited |
Il10 sarna compositions and methods of use
|
WO2023183909A2
(en)
|
2022-03-25 |
2023-09-28 |
Modernatx, Inc. |
Polynucleotides encoding fanconi anemia, complementation group proteins for the treatment of fanconi anemia
|
WO2024015741A1
(en)
|
2022-07-12 |
2024-01-18 |
Gilead Sciences, Inc. |
Hiv immunogenic polypeptides and vaccines and uses thereof
|
TW202412818A
(zh)
|
2022-07-26 |
2024-04-01 |
美商現代公司 |
用於暫時控制表現之經工程化多核苷酸
|
WO2024134199A1
(en)
|
2022-12-22 |
2024-06-27 |
Mina Therapeutics Limited |
Chemically modified sarna compositions and methods of use
|